Publications

February 27, 2026
Nasal epinephrine spray for anaphylaxis: which is better – powder or liquid?
Lapidot et. al. American Academy of Allergy, Asthma & Immunology (AAAAI) 2026
February 27, 2026
FMXIN002 Epinephrine Intranasal Powder Spray is Stable Throughout 3 Freeze-Thaw Cycles
Lapidot et. al. American Academy of Allergy, Asthma & Immunology (AAAAI) 2026
April 1, 2025
First-in-class intranasal epinephrine spray for anaphylaxis: Dose finding clinical study
Lapidot et. al. Journal of Allergy and Clinical Immunology: 2025, Global, Volume 4, Issue 3, 100487, doi: 10.1016/j.jacig.2025.100487
February 25, 2025
Fast Acting, 5 years stable Intra-Nasal Powder-Spray Epinephrine for Anaphylaxis: Integrated Analysis of Two Clinical Trials
Tal, Lapidot et. al. American Academy of Allergy, Asthma & Immunology (AAAAI) 2025
July 1, 2023
Fast Acting, Dry Powder, Needle-Free, Intranasal Epinephrine Spray: A Promising Future Treatment for Anaphylaxis
Tal et. al. J Allergy Clin Immunol Pract. 2023 Oct;11(10):3047-3054. doi: 10.1016/j.jaip.2023.06.044
July 14, 2022
A new fast acting naloxone powder nasal spray for opioid overdose
Lapidot et. al. American Society of Pain & Neuroscience (ASPN), 2022
March 1, 2022
A Novel Faster‑Acting, Dry Powder‑Based, Naloxone Intranasal Formulation for Opioid Overdose
Lapidot et. al. Pharm Res 39, 963–975 (2022). doi: 10.1007/s11095-022-03247-5
Scroll to Top
Secret Link